Eli Lilly Teams Up with Insilico Medicine in $2.75 Billion AI-Driven Drug Deal

March 30, 2026

Pharmaceutical giant Eli Lilly has solidified a groundbreaking deal worth $2.75 billion with Hong Kong-listed Insilico Medicine to introduce AI-developed drugs globally. The agreement involves Insilico's cutting-edge artificial intelligence technology.....

Subscribe for Full Access!

Gain valuable sourcing and trade intelligence from our database of millions of data points spanning 20+ years!

Subscribe!

Key Data Topics AI-driven drugs, biotech innovation, China investment, drug development, Eli Lilly, healthcare market, Insilico Medicine, pharmaceutical industry

Share this Data

Other Sourcing Intelligence

Breakthrough in EV Battery Technology: China Leads the Charge with 11-Minute Charging Sodium-Ion Battery

March 30, 2026

China Accelerates the Race to Ultrafast Electric Vehicle Charging

March 30, 2026

PetroChina's Profit Decline Amid Oil Price Drop and Demand Pangs

March 29, 2026

Guardian Bike Company Upholds American Manufacturing Amidst Tariff Debates

March 29, 2026

Adapting Strategies: Clean Energy Firms in Challenging Times

March 29, 2026

Chinese Import Yuan Leads Wanderers to Victory as Wellington Hands Melbourne City ALW Title

March 29, 2026